Cargando…
Association of homogeneous inflamed gene signature with a better outcome in patients with metastatic melanoma treated with MAGE-A3 immunotherapeutic
PURPOSE: This study assessed clinical activity, safety and immunogenicity of MAGE-A3 immunotherapeutic in patients with MAGE-A3-positive metastatic melanoma. PATIENTS AND METHODS: In this open-label, multicentre, uncontrolled, Phase II study (ClinicalTrials.gov NCT00896480), patients received ≤24 do...
Autores principales: | Baurain, Jean-François, Robert, Caroline, Mortier, Laurent, Neyns, Bart, Grange, Florent, Lebbe, Céleste, Ulloa-Montoya, Fernando, De Sousa Alves, Pedro Miguel, Gillet, Marc, Louahed, Jamila, Jarnjak, Silvija, Lehmann, Frédéric F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069918/ https://www.ncbi.nlm.nih.gov/pubmed/30094070 http://dx.doi.org/10.1136/esmoopen-2018-000384 |
Ejemplares similares
-
Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature
por: Grob, Jean-Jacques, et al.
Publicado: (2017) -
Tumor Mouse Model Confirms MAGE-A3 Cancer Immunotherapeutic As an Efficient Inducer of Long-Lasting Anti-Tumoral Responses
por: Gérard, Catherine, et al.
Publicado: (2014) -
P25. Access to diagnostics: a bottleneck for immunotherapeutics development - case example of MAGE-A3 cancer immunotherapeutic
por: Lykopoulos, K, et al.
Publicado: (2014) -
Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study
por: Gutzmer, R, et al.
Publicado: (2016) -
Pathogenicity of the MAGE family
por: Li, Sanyan, et al.
Publicado: (2021)